Does the FDA’s KOURAGE response restore confidence in CalciMedica’s CRAC platform?
CalciMedica can continue developing Auxora after the FDA reviewed KOURAGE safety data without imposing a clinical hold, but a large financing, major potential dilution and a strategic shift toward pulmonary hypertension redefine the CALC investment case.